Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fort Worth Clinical Sciences Working Group (FWCSWG) for COVID-19: Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients

NCT05013034 is registered in ClinicalTrials.gov with Fort Worth Clinical Sciences Working Group as lead sponsor.

NCT NCT05013034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05013034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fort Worth Clinical Sciences Working Group (FWCSWG) for COVID-19: Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
Lead sponsor
Fort Worth Clinical Sciences Working Group
Phase
Phase 2
Overall status
Unknown status
Start date
October 15, 2021
Completion date
December 1, 2022
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine storm, sars-cov-2 acute respiratory disease, sars-cov2 infection